Clamp Andrew, Danson Sarah, Nguyen Huy, Cole David, Clemons Mark
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.
Lancet Oncol. 2004 Oct;5(10):607-16. doi: 10.1016/S1470-2045(04)01596-7.
Metastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.
转移性骨病在癌症患者中很常见，会导致大量与疾病相关的发病率和死亡率。然而，有几种有效的治疗方法可用于管理这些患者。双膦酸盐可抑制破骨细胞介导的骨基质吸收，尤为重要，因为它们可降低多种肿瘤类型中骨相关事件的发生率，并可补充抗肿瘤治疗。目前，由于缺乏有效、快速的方法来测量疾病反应，骨转移治疗的评估受到阻碍。我们讨论了当前反应评估措施的困难，并描述了骨转移新的放射学和生化标志物的发展。目前，检测I型胶原末端肽作为骨吸收标志物的检测方法似乎最有前景。
